NewcelX Ltd. business relationships

Companies named in NewcelX Ltd.’s 20-F filed 2026-04-29, and public companies whose annual reports name NewcelX Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 4.0 / 10
AI naming: <1 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in NewcelX Ltd.’s annual report 5

Merck & Co., Inc. (MRK)Customer7.7
“later sold to Merck Serono.” SEC filing
NOVARTIS AG (NVS)Licensor7.7
“| License Agreement by and between NewcelX Ltd. and Novartis Pharma AG, dated March 10, 2021 (filed as Exhibit 4.6 to Annual Report on Form 20-F filed on May 14, 2021). |” SEC filing
Eledon Pharmaceuticals, Inc. (ELDN)Partner4.6
“Eledon Pharmaceuticals as well as other collaboration agreements with third parties.” SEC filing
Aexon Labs Inc.Licensor4.0
“license agreement with Aexon Labs Inc. (the "Aexon Agreement").” SEC filing
E.ON (EONGY)Licensor-
“| | E. | | On January 26, 2015, the Company entered into a research and license agreement with Ramot at Tel Aviv University Ltd. (hereinafter, "Ramot") and scientist Professor Shimon Efrat, for the development and commercialization of therapeutic products to accelerate the development of a cellular...” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.